We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current AVE market cap is 19.02M. The company's latest EPS is AUD -0.0010 and P/E is -10.00.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 991k | 1.92M | 1.87M | 1.59M | 2.93M |
| Operating Income | -2.8M | -3.38M | -2.36M | -3.48M | -3.16M |
| Net Income | -2.64M | -3.42M | -2.34M | -3.44M | -3.12M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 3.36M | 5.25M | 3.35M | 7.32M | 5M |
| Total Liabilities | 700k | 709k | 921k | 941k | 1.73M |
| Total Equity | 2.66M | 4.54M | 2.43M | 6.38M | 3.27M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -1.42M | -3.1M | -1.67M | -3.18M | -3.97M |
| Investing | -4k | -203k | -53k | N/A | -16k |
| Financing | -83k | 4.69M | -78k | 7.22M | 855k |
| Market Cap | 19.02M |
| Price to Earnings Ratio | -10.00 |
| Price to Sales Ratio | 11.11 |
| Price to Cash Ratio | 14.29 |
| Price to Book Ratio | 9.69 |
| Dividend Yield | - |
| Shares Outstanding | 3.17B |
| Average Volume (1 week) | 21.9M |
| Average Volume (1 Month) | 22.25M |
| 52 Week Change | 50.00% |
| 52 Week High | 0.009 |
| 52 Week Low | 0.001 |
| Spread (Intraday) | 0 (28.57%) |
| Company Name | Avecho Biotechnology Limited |
| Address |
unit a8, 2a westall road melbourne, victoria 3168 |
| Website | https://www.avecho.com.au |
| Industry | financial services div'd (F3) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
